Marquet Magda 4

What Happened

• Director Magda Marquet received equity awards from Immix Biopharma (IMMX) on May 22, 2026. The filing shows two grants totaling 18,750 shares: 6,250 restricted stock units (RSUs) and a 12,500-share derivative award (stock option/other derivative). Both awards were granted at a $0 acquisition price (i.e., they were awards, not purchases).

Key Details

• Transaction date: May 22, 2026; Filing date: May 29, 2026 (filed 7 days after the grants).
• Awards: 6,250 RSUs + 12,500-share derivative award = 18,750 total shares; acquisition price $0 for each grant.
• Vesting:
  • 6,250 RSUs vest in full on the earlier of the one-year anniversary of the grant or the Issuer’s 2027 annual meeting, subject to continued service (Footnote F1).
  • The 12,500 derivative award vests in substantially equal monthly installments over 12 months (or any remaining unvested portion vests on the 2027 annual meeting if it occurs earlier), subject to continued board service (Footnote F3).
• Shares owned after the transaction are not specified in the excerpt provided. Footnote F2 notes Marquet’s association with Alma Life Sciences, LLC and that she may be deemed to beneficially own securities held by that entity, though she disclaims beneficial ownership except to the extent of pecuniary interest.
• Timeliness: The Form 4 was filed 7 days after the transaction date, later than the typical two-business-day reporting window for Form 4s.

Context

• These were awarded grants (compensation/retention), not open-market purchases or sales; awards are common for directors and are subject to vesting and continued service conditions.
• The 12,500-share item is a derivative award (an option-like instrument) that vests over time—it is not an immediate sale or cash transaction.
• The late filing may delay market visibility into insider compensation but does not, by itself, indicate intent or opinion about the company’s prospects.